Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31260890 | 1.00 | KDM4E (0.42) | KDM4ENFE2L2ACHEBACE1CA12 | |
| SCHEMBL5019590 | 0.82 | NFE2L2 (0.46) | KDM4ENFE2L2ACHEBACE1CA12 | |
| SCHEMBL166380 | 0.78 | NFE2L2 (0.61) | KDM4ENFE2L2ACHECA12CA1 | |
| SCHEMBL18472613 | 0.78 | NFE2L2 (0.61) | KDM4ENFE2L2ACHECA12CA1 | |
| SCHEMBL24313718 | 0.77 | L3MBTL1 (0.44) | KDM4ECYP1A2CYP2C19MEN1MAPT | |
| SCHEMBL29469827 | 0.77 | L3MBTL1 (0.44) | KDM4ECYP1A2CYP2C19MEN1MAPT | |
| SCHEMBL24017203 | 0.77 | APP (0.43) | CA12CA1CA2CA4CA7 | |
| SCHEMBL197234 | 0.76 | APP (0.38) | ACHECA12CA1CA2CA4 | |
| SCHEMBL29362946 | 0.76 | MEN1 (0.46) | KDM4ENFE2L2CA12CA1CA2 | |
| SCHEMBL4307124 | 0.76 | ALDH1A1 (0.54) | KDM4EPDGFRBPDGFRACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| WO-2023020209-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-02-23 | — | — | WO | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3865475-A1 | PROCESS FOR PREPARING PYRIDONE AMIDES WHICH ARE MODULATORS OF SODIUM CHANNELS AND INTERMEDIATE COMPOUNDS USED THEREIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021047622-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-18 | — | — | WO | disclosed |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-10-29 | — | — | US | disclosed |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-10-29 | — | — | US | disclosed |
| EP-3693365-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| EP-3693365-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020108500-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | 成都海创药业有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2094692-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8067447-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2011112662-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | KDM4E 773/4885NFE2L2 2196/4885ACHE 3781/4885 |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | EGFR, ERBB2, ERBB3 | KDM4E 4716/4885NFE2L2 1202/4885ACHE 4651/4885 |
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | KDM4E 1851/4885NFE2L2 105/4885ACHE 4501/4885 |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | KDM4E 246/4885NFE2L2 2211/4885ACHE 1958/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | KDM4E 773/4885NFE2L2 2196/4885ACHE 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.